- Home
- NSA vs BEAM Comparison
NSA vs BEAM Comparison
Compare NSA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSA
- BEAM
- Stock Information
- Founded
- NSA 2013
- BEAM 2017
- Country
- NSA United States
- BEAM United States
- Employees
- NSA N/A
- BEAM N/A
- Industry
- NSA Real Estate Investment Trusts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NSA Real Estate
- BEAM Health Care
- Exchange
- NSA Nasdaq
- BEAM Nasdaq
- Market Cap
- NSA 2.3B
- BEAM 2.6B
- IPO Year
- NSA 2015
- BEAM 2020
- Fundamental
- Price
- NSA $31.62
- BEAM $27.84
- Analyst Decision
- NSA Hold
- BEAM Strong Buy
- Analyst Count
- NSA 8
- BEAM 11
- Target Price
- NSA $34.25
- BEAM $49.40
- AVG Volume (30 Days)
- NSA 1.1M
- BEAM 2.5M
- Earning Date
- NSA 11-03-2025
- BEAM 11-05-2025
- Dividend Yield
- NSA 7.20%
- BEAM N/A
- EPS Growth
- NSA N/A
- BEAM N/A
- EPS
- NSA 0.61
- BEAM N/A
- Revenue
- NSA $741,255,000.00
- BEAM $60,272,000.00
- Revenue This Year
- NSA N/A
- BEAM N/A
- Revenue Next Year
- NSA $2.62
- BEAM $19.01
- P/E Ratio
- NSA $51.56
- BEAM N/A
- Revenue Growth
- NSA N/A
- BEAM N/A
- 52 Week Low
- NSA $28.02
- BEAM $13.53
- 52 Week High
- NSA $46.07
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- NSA 53.89
- BEAM 57.97
- Support Level
- NSA $31.35
- BEAM $26.90
- Resistance Level
- NSA $32.79
- BEAM $31.54
- Average True Range (ATR)
- NSA 0.69
- BEAM 2.15
- MACD
- NSA 0.12
- BEAM -0.03
- Stochastic Oscillator
- NSA 61.42
- BEAM 53.68
About NSA National Storage Affiliates Trust of Beneficial Interest
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.